- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Online drugstores lack appeal
According to the Greenwich, CT-based market research company InsightExpress, online consumers are staying away from online pharmacies.
According to the Greenwich, CT-based market research company InsightExpress, online consumers are staying away from online pharmacies. According to a survey of 300 adult online consumers, 93% of respondents have never made a purchase from an online drugstore, and 76% have never even visited an online drugstore site.
"The online drugstore business model makes sense in theory, but not in practice," said Charles Hamlin, president of InsightExpress. "It's not gaining traction in the online marketplace, mainly because people desire the personal interaction they receive with the local pharmacist. There's an extraordinary difference between buying a CD online and discussing side effects and proper dosages."
According to InsightExpress, the future does not look good. When asked about prospective buying intent, 57% of respondents stated that they probably would not purchase prescription drugs online, and 31% were undecided. Only 12% of respondents said they would likely purchase prescriptions online in the future. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
